Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

The products currently sold or approved by Celltrion in Australia include autoimmune disease treatments such as Remsima, Remsima SC, Uplyma, and Steqeyma, as well as anticancer drugs like Herzuma ...

This month, Hanmi Pharmaceuticals and Samsung Bioepis entered into an agreement to develop and commercialize a denosumab biosimilar (SB16) referencing Amgen’s PROLIA ® in Korea. PROLIA ® is ...

The ustekinumab biosimilar market is rapidly expanding, with 2 more competitors—Celltrion’s Steqeyma and Fresenius Kabi/Formycon’s Otulfi—joining the lineup of lower-cost alternatives to Janssen’s ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...